British and Swedish pharmaceutical company AstraZeneca and the U.S.AI（AI) Biologics Company Absci Signed a $247 million agreement to design aAnti-cancerThe company has developed antibodies to fight the disease, Absci said in a statement on Sunday.
Absci’s collaboration with AstraZeneca aims to develop a zero-shot AI model designed to create new and improved antibody therapeutics. The company did not say which types of cancer they plan to target.
Absci applies generative AI to design products based on target affinity, safety, manufacturability, and other characteristics.optimalDrug candidates.
Absci CEO Sean McClain said: “We are proud to be working closely with AstraZeneca to use our AI toTumorPatients bring new treatment options.”
According to the Financial Timesfirstreported the deal, which includes a one-time fee for Absci, research and development funding, payments for achieving milestones, and royalties on any product sales.
